Sept. 29, 2017 (TORONTO and ST. LOUIS) — CCRM, a leader in the development and commercialization of regenerative medicine technologies, cell and gene therapies and Affigen, a biotechnology company that is developing therapeutics that target cell lineage-specific tumor proteins, are pleased to announce a new partnership that will advance the creation and commercialization of a […]
This author has yet to write their bio.Meanwhile lets just say that we are proud fswpadmin contributed a whooping 3 entries.
Entries by fswpadmin
Funding for Development of Cancer Immunotherapies Targeting Cell Lineage-Specific Tumor Proteins Feb. 21, 2017 (ST. LOUIS and HOUSTON) — Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, today announced the closing of a $17 million Series A financing round led by Black Beret Life Sciences on behalf of its affiliate BBLS […]
We’re hiring! Affigen has several open positions, and we’re looking for talented individuals across all areas of the company to help us achieve our goals.
+1 (512) 220-7502
1601 Trinity St.
Building B, Suite 3.306
Austin, TX 78712